Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

KMT2A rearranged infant acute lymphoblastic leukemia patients have a poor prognosis. Here, the authors use high throughput drug screening on primary infant specimens to identify a clinically active chemotherapy combination.

Bibliographic Details
Main Authors:	Jennifer L. Kamens, Stephanie Nance, Cary Koss, Beisi Xu, Anitria Cotton, Jeannie W. Lam, Elizabeth A. R. Garfinkle, Pratima Nallagatla, Amelia M. R. Smith, Sharnise Mitchell, Jing Ma, Duane Currier, William C. Wright, Kanisha Kavdia, Vishwajeeth R. Pagala, Wonil Kim, LaShanale M. Wallace, Ji-Hoon Cho, Yiping Fan, Aman Seth, Nathaniel Twarog, John K. Choi, Esther A. Obeng, Mark E. Hatley, Monika L. Metzger, Hiroto Inaba, Sima Jeha, Jeffrey E. Rubnitz, Junmin Peng, Taosheng Chen, Anang A. Shelat, R. Kiplin Guy, Tanja A. Gruber
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-02-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-023-36370-x

Internet

https://doi.org/10.1038/s41467-023-36370-x